This Is MS Multiple Sclerosis Knowledge & Support Community

Posted: **Sat Jun 05, 2010 5:23 pm**

Teva announces positive results from a study assessing a new formulation of Copaxone.

<shortened url>

Posted: **Fri Jun 18, 2010 3:34 pm**

The text seems to contradict the conclusion of the study - 12.5% vs 18.1% for those with the new formulation suggests a relative risk INCREASE of nearly 50% for tolerability problems with the new formulation.

A typo? Anybody have a link to the original paper?

Adverse events were reported by 12.5 percent of patients when injecting 20mg/1.0mL and by 18.1 percent of patients when injecting 20mg/0.5mL.